胚系RUNX1变异伴髓系恶性肿瘤家族性血小板疾病患者的基因组图谱
该纵向自然病史研究纳入截至2021年底有研究基因组数据的27个家族,检出26种不同胚系RUNX1变异,51例无血液系统恶性肿瘤患者中25例(49%)检出至少1个CHIP或AML驱动基因的体细胞突变,BCOR突变最常见(9例),连续测序显示体细胞突变随时间动态变化,稳定克隆在老年患者中更常见。
要点
- 27个家族中检出26种不同胚系RUNX1变异,包括错义、功能缺失、剪接区及大片段缺失。
- 51例无血液系统恶性肿瘤患者中25例(49%)检出CHIP或AML驱动基因体细胞突变,BCOR突变最常见(9例)。
- 连续测序显示体细胞突变随时间动态变化,稳定克隆在老年患者中更常见。
核心结论
- FPDMM患者中胚系RUNX1变异类型多样,且克隆性造血相关体细胞突变频率高。
- 前瞻性监测体细胞突变变化和临床表现可能揭示恶性进展机制并为临床管理提供信息。
研究设计与样本
- 纵向自然病史研究,纳入截至2021年底有研究基因组数据的27个家族。
- 该试验在www.clinicaltrials.gov注册,注册号为NCT03854318。
主要发现
- 27个家族中检出26种不同胚系RUNX1变异,剪接区突变见于6个家族,大片段缺失见于7个家族。
- 51例无血液系统恶性肿瘤患者中25例(49%)检出至少1个CHIP基因或AML驱动基因的体细胞突变。
- BCOR是最常突变的基因(9例患者),4例患者检出多个BCOR突变。
- 6个其他CHIP或AML驱动基因(TET2、DNMT3A、KRAS、LRP1B、IDH1和KMT2C)在≥2例无血液系统恶性肿瘤患者中检出。
- 3例无亲缘关系患者(1例伴髓系恶性肿瘤)携带NFE2体细胞突变,NFE2调控红系和巨核细胞分化。
临床怎么用
- 作者认为,前瞻性监测体细胞突变变化和临床表现可能揭示恶性进展机制并为临床管理提供信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Familial platelet disorder with associated myeloid malignancies (FPDMM) is caused by germline RUNX1 mutations and characterized by thrombocytopenia and increased risk of hematologic malignancies. We recently launched a longitudinal natural history study for patients with FPDMM. Among 27 families with research genomic data by the end of 2021, 26 different germline RUNX1 variants were detected. Besides missense mutations enriched in Runt homology domain and loss-of-function mutations distributed throughout the gene, splice-region mutations and large deletions were detected in 6 and 7 families, respectively. In 25 of 51 (49%) patients without hematologic malignancy, somatic mutations were detected in at least 1 of the clonal hematopoiesis of indeterminate potential (CHIP) genes or acute myeloid leukemia (AML) driver genes. BCOR was the most frequently mutated gene (in 9 patients), and multiple BCOR mutations were identified in 4 patients. Mutations in 6 other CHIP- or AML-driver genes (TET2, DNMT3A, KRAS, LRP1B, IDH1, and KMT2C) were also found in ≥2 patients without hematologic malignancy. Moreover, 3 unrelated patients (1 with myeloid malignancy) carried somatic mutations in NFE2, which regulates erythroid and megakaryocytic differentiation. Sequential sequencing data from 19 patients demonstrated dynamic changes of somatic mutations over time, and stable clones were more frequently found in older adult patients. In summary, there are diverse types of germline RUNX1 mutations and high frequency of somatic mutations related to clonal hematopoiesis in patients with FPDMM. Monitoring changes in somatic mutations and clinical manifestations prospectively may reveal mechanisms for malignant progression and inform clinical management. This trial was registered at www.clinicaltrials.gov as #NCT03854318.
引用
- Yu K, Deuitch N, Merguerian M, et al. Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. Blood Adv. 2024. PMID: 38019014. doi:10.1182/bloodadvances.2023011165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。